© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Vaxart, Inc. (VXRT) stock surged +6.89%, trading at $0.82 on NASDAQ, up from the previous close of $0.76. The stock opened at $0.75, fluctuating between $0.75 and $0.82 in the recent session.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Employees | 109 |
Beta | 0.7 |
Sales or Revenue | $7.38M |
5Y Sales Change% | -0.923% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Vaxart, Inc. (NASDAQ: VXRT) stock price is $0.82 in the last trading session. During the trading session, VXRT stock reached the peak price of $0.82 while $0.75 was the lowest point it dropped to. The percentage change in VXRT stock occurred in the recent session was 6.89% while the dollar amount for the price change in VXRT stock was $0.05.
The NASDAQ listed VXRT is part of Biotechnology industry that operates in the broader Healthcare sector. Vaxart, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Sean N. Tucker
Senior Vice President & Chief Scientific Officer
Mr. John M. Harland M.B.A., CPA
Consultant
Dr. Rajesh Kapoor Ph.D.
Senior Vice President of Quality
Mr. Phillip Eric Lee
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Mr. Cezar Andrei Floroiu M.B.A.
Chief Executive Officer, Pres & Director
Dr. Sean N. Tucker Ph.D.
Senior Vice President & Chief Scientific Officer
Dr. James F. Cummings M.D.
Chief Medical Officer
Dr. Raymond D. Stapleton Jr., Ph.D.
Chief Technology Officer
Mr. Edward B. Berg
Senior Vice President & Gen. Counsel
Ms. Sarah Caravalho Khan
Vice President & Head of HR
Ms. Shaily Jaini Garg
Senior Vice President of Clinical Devel. & Project Management
Mr. Brant Biehn
Senior Vice President of Bus. Operations
VXRT's closing price is 57.15% higher than its 52-week low of $0.52 where as its distance from 52-week high of $1.54 is -46.94%.
Number of VXRT employees currently stands at 109.
Official Website of VXRT is: https://vaxart.com
VXRT could be contacted at phone 650 550 3500 and can also be accessed through its website. VXRT operates from 170 Harbor Way, South San Francisco, CA 94080, United States.
VXRT stock volume for the day was 1.29M shares. The average number of VXRT shares traded daily for last 3 months was 1.81M.
The market value of VXRT currently stands at $185.90M with its latest stock price at $0.82 and 227.48M of its shares outstanding.